FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2576460558> ?p ?o ?g. }

• W2576460558 abstract "Background: The Akt1 E17K mutation results in pathological localization of Akt1 to the plasma membrane, stimulating constitutive downstream signaling via oncogenic Akt effector pathways. This mutation is observed in various solid tumors, eg breast (4%), bladder (2%), colorectal (1.5%), cervical (1%), ovarian (1%), prostate (1%) and lung adenocarcinoma (0.5%). Whether Akt1 E17K represents an oncogenic driver and rational drug target in these tumor types is unknown. Here we present preliminary data from patients (pts) with Akt1 E17K mutant advanced solid tumors treated with an oral selective Akt kinase inhibitor, AZD5363, in two Phase 1 studies (NCT01226316, NCT01353781).Methods: Eligible pts had advanced solid tumors refractory to standard treatments and measurable disease by RECIST v1.1. For NCT01226316, Akt1 E17K mutation status was prospectively confirmed on archival or fresh tumor samples prior to enrollment; pts with known RAS mutations were excluded. In NCT01353781, Akt1 E17K mutation status was retrospectively assessed in a subset of enrolled pts. For all pts except one, AZD5363 was administered orally at a starting dose of 480mg bid on a ?4 days on/3 days off? schedule. Investigator-assessed RECIST responses were determined every 6 wks for 6 mths, then every 12 wks. Serial plasma samples were collected for detection and tracking of Akt1 E17K mutation (expressed as the mutant allele fraction [MAF]) in circulating tumor DNA (ctDNA) by droplet digital PCR.Results: 33 pts with known Akt1 E17K mutant tumors have been treated to date: estrogen receptor positive (ER+) breast (n=15), triple-negative breast (TNBC; n=4), gynecological (4 endometrial, 2 cervical, 2 ovarian, 1 fallopian; n=9) and other (n=5). 29 pts were evaluable for response. Overall, 20/29 pts (69%) demonstrated target lesion regression. RECIST partial responses (PRs) have been observed in 6 pts (5 confirmed, 1 unconfirmed); ER+ breast cancer (n=2), lung adenocarcinoma (n=1), cervical squamous cancer (n=1), endometrioid ovarian cancer (n=1) and TNBC (n=1, unconfirmed). Median duration on study for the PR pts was 8.3 mths (range 2.4-38.1), with 4/5 maintaining PR. Overall, 15/29 (52%) pts had an on-study duration of ?4 mths and 14/33 (42%) continue on study. Serial ctDNA assessments were available in 15/33 pts. The Akt1 E17K mutation was detectable in ctDNA in 14/15 (93%) pts at baseline. Akt1 ctDNA declined in 13/14 (93%) pts and became entirely undetectable in 6/13 (46%) pts, 3 of whom attained a PR. Declines in Akt1 ctDNA were transient in non-responders, while persistent declines (?21 days) correlated with durable tumor regression and RECIST response (P=0.0061). Rise in Akt1 ctDNA preceded clinicoradiological progression by a median of 37 days (range 17-104) in 7/7 (100%) assessable pts. Safety profile of AZD5363 was consistent with previous reports; the most common AEs were diarrhea, rash and hyperglycemia.Conclusions: The Akt1 E17K mutation is an actionable genomic alteration in several solid tumor types. AZD5363 monotherapy shows promising clinical activity in various heavily pre-treated Akt1 E17K mutant solid tumors, including ER+ breast, cervical and ovarian cancer, and lung adenocarcinoma. ctDNA may enable prediction of clinicoradiological response and eventual progression. NCT01226316 continues to accrue pts with Akt1 E17K mutant solid tumors and updated results will be presented." @default.
• W2576460558 created "2017-01-26" @default.
• W2576460558 creator A5004112011 @default.
• W2576460558 creator A5005475609 @default.
• W2576460558 creator A5006752459 @default.
• W2576460558 creator A5018855642 @default.
• W2576460558 creator A5020149153 @default.
• W2576460558 creator A5020460270 @default.
• W2576460558 creator A5025261280 @default.
• W2576460558 creator A5026269100 @default.
• W2576460558 creator A5032401979 @default.
• W2576460558 creator A5041961484 @default.
• W2576460558 creator A5043738572 @default.
• W2576460558 creator A5044955545 @default.
• W2576460558 creator A5051322178 @default.
• W2576460558 creator A5056491116 @default.
• W2576460558 creator A5064206219 @default.
• W2576460558 creator A5067985450 @default.
• W2576460558 creator A5068193017 @default.
• W2576460558 creator A5069337573 @default.
• W2576460558 creator A5069965708 @default.
• W2576460558 creator A5071204980 @default.
• W2576460558 creator A5072712459 @default.
• W2576460558 creator A5076090440 @default.
• W2576460558 creator A5077979726 @default.
• W2576460558 creator A5085819010 @default.
• W2576460558 creator A5091455253 @default.
• W2576460558 date "2015-11-09" @default.
• W2576460558 modified "2023-09-26" @default.
• W2576460558 title "AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors" @default.
• W2576460558 hasPublicationYear "2015" @default.
• W2576460558 type Work @default.
• W2576460558 sameAs 2576460558 @default.
• W2576460558 citedByCount "1" @default.
• W2576460558 countsByYear W25764605582018 @default.
• W2576460558 crossrefType "journal-article" @default.
• W2576460558 hasAuthorship W2576460558A5004112011 @default.
• W2576460558 hasAuthorship W2576460558A5005475609 @default.
• W2576460558 hasAuthorship W2576460558A5006752459 @default.
• W2576460558 hasAuthorship W2576460558A5018855642 @default.
• W2576460558 hasAuthorship W2576460558A5020149153 @default.
• W2576460558 hasAuthorship W2576460558A5020460270 @default.
• W2576460558 hasAuthorship W2576460558A5025261280 @default.
• W2576460558 hasAuthorship W2576460558A5026269100 @default.
• W2576460558 hasAuthorship W2576460558A5032401979 @default.
• W2576460558 hasAuthorship W2576460558A5041961484 @default.
• W2576460558 hasAuthorship W2576460558A5043738572 @default.
• W2576460558 hasAuthorship W2576460558A5044955545 @default.
• W2576460558 hasAuthorship W2576460558A5051322178 @default.
• W2576460558 hasAuthorship W2576460558A5056491116 @default.
• W2576460558 hasAuthorship W2576460558A5064206219 @default.
• W2576460558 hasAuthorship W2576460558A5067985450 @default.
• W2576460558 hasAuthorship W2576460558A5068193017 @default.
• W2576460558 hasAuthorship W2576460558A5069337573 @default.
• W2576460558 hasAuthorship W2576460558A5069965708 @default.
• W2576460558 hasAuthorship W2576460558A5071204980 @default.
• W2576460558 hasAuthorship W2576460558A5072712459 @default.
• W2576460558 hasAuthorship W2576460558A5076090440 @default.
• W2576460558 hasAuthorship W2576460558A5077979726 @default.
• W2576460558 hasAuthorship W2576460558A5085819010 @default.
• W2576460558 hasAuthorship W2576460558A5091455253 @default.
• W2576460558 hasConcept C104317684 @default.
• W2576460558 hasConcept C11960822 @default.
• W2576460558 hasConcept C126322002 @default.
• W2576460558 hasConcept C143998085 @default.
• W2576460558 hasConcept C154137905 @default.
• W2576460558 hasConcept C501734568 @default.
• W2576460558 hasConcept C502942594 @default.
• W2576460558 hasConcept C55493867 @default.
• W2576460558 hasConcept C71924100 @default.
• W2576460558 hasConcept C75217442 @default.
• W2576460558 hasConcept C86803240 @default.
• W2576460558 hasConcept C88216763 @default.
• W2576460558 hasConceptScore W2576460558C104317684 @default.
• W2576460558 hasConceptScore W2576460558C11960822 @default.
• W2576460558 hasConceptScore W2576460558C126322002 @default.
• W2576460558 hasConceptScore W2576460558C143998085 @default.
• W2576460558 hasConceptScore W2576460558C154137905 @default.
• W2576460558 hasConceptScore W2576460558C501734568 @default.
• W2576460558 hasConceptScore W2576460558C502942594 @default.
• W2576460558 hasConceptScore W2576460558C55493867 @default.
• W2576460558 hasConceptScore W2576460558C71924100 @default.
• W2576460558 hasConceptScore W2576460558C75217442 @default.
• W2576460558 hasConceptScore W2576460558C86803240 @default.
• W2576460558 hasConceptScore W2576460558C88216763 @default.
• W2576460558 hasLocation W25764605581 @default.
• W2576460558 hasOpenAccess W2576460558 @default.
• W2576460558 hasPrimaryLocation W25764605581 @default.
• W2576460558 hasRelatedWork W1992310449 @default.
• W2576460558 hasRelatedWork W2006827588 @default.
• W2576460558 hasRelatedWork W2018320891 @default.
• W2576460558 hasRelatedWork W2021945328 @default.
• W2576460558 hasRelatedWork W2026890779 @default.
• W2576460558 hasRelatedWork W2060433771 @default.
• W2576460558 hasRelatedWork W2152248266 @default.
• W2576460558 hasRelatedWork W2271296522 @default.
• W2576460558 hasRelatedWork W2336132036 @default.
• W2576460558 hasRelatedWork W2404235140 @default.
• W2576460558 hasRelatedWork W2477809124 @default.
• W2576460558 hasRelatedWork W2591102489 @default.

• next